AbbVie’s hepatitis C treatment shows promise

(Reuters) - Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks…
Read the full story: Reuters: Health News